assembly Bill A7196A

2019-2020 Legislative Session

Enacts the manufacturer disclosure and transparency act

download bill text pdf

Sponsored By

Current Bill Status - In Assembly Committee


  • Introduced
  • In Committee
  • On Floor Calendar
    • Passed Senate
    • Passed Assembly
  • Delivered to Governor
  • Signed/Vetoed by Governor

Your Voice

do you support this bill?

Please enter your contact information

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.

Actions

view actions (4)
Assembly Actions - Lowercase
Senate Actions - UPPERCASE
Feb 05, 2020 print number 7196a
Feb 05, 2020 amend (t) and recommit to consumer affairs and protection
Jan 08, 2020 referred to consumer affairs and protection
Apr 12, 2019 referred to consumer affairs and protection

Co-Sponsors

view additional co-sponsors

A7196 - Details

See Senate Version of this Bill:
S5169
Law Section:
General Business Law
Laws Affected:
Add §396-rrr, Gen Bus L

A7196 - Summary

Enacts the manufacturer disclosure and transparency act requiring prescription drug manufacturers to notify the attorney general of arrangements between pharmaceutical manufacturers resulting in the delay of the introduction of generic medications.

A7196 - Bill Text download pdf

 
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
     S. 5169                                                  A. 7196
 
                        2019-2020 Regular Sessions
 
                       S E N A T E - A S S E M B L Y
 
                              April 12, 2019
                                ___________
 
 IN  SENATE -- Introduced by Sen. BIAGGI -- read twice and ordered print-
   ed, and when printed to be committed  to  the  Committee  on  Consumer
   Protection
 
 IN  ASSEMBLY  --  Introduced  by  M.  of  A.  DenDEKKER -- read once and
   referred to the Committee on Consumer Affairs and Protection

 AN ACT to amend the general  business  law,  in  relation  to  requiring
   prescription  drug  manufacturers  to  notify  the attorney general of
   agreements between pharmaceutical manufacturers resulting in the delay
   of the introduction of generic drugs
 
   THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section  1.  This act shall be known and may be cited as the "manufac-
 turer disclosure and transparency act".
   § 2. The general business law is amended by adding a new section  396-
 rrr to read as follows:
   §  396-RRR.  DELAY OF INTRODUCTION OF GENERIC MEDICATIONS. 1. (A) EACH
 PHARMACEUTICAL MANUFACTURER DOING BUSINESS IN THIS STATE  THAT  MANUFAC-
 TURES  A  BRAND NAME PRESCRIPTION DRUG AND ENTERS INTO AN AGREEMENT WITH
 ANOTHER PHARMACEUTICAL MANUFACTURER  FOR  THE  PURPOSE  OF  DELAYING  OR
 PREVENTING SUCH OTHER MANUFACTURER FROM INTRODUCING A GENERIC SUBSTITUTE
 FOR  SUCH  DRUG  INTO  THE MARKETPLACE SHALL, NOT LATER THAN THIRTY DAYS
 AFTER ENTERING INTO SUCH AGREEMENT, SEND NOTICE TO THE ATTORNEY GENERAL,
 IN A FORM AND MANNER PRESCRIBED BY THE ATTORNEY GENERAL, DISCLOSING  THE
 NAME OF SUCH DRUG, THE WHOLESALE PRICE, THE DISEASE SUCH DRUG IS COMMON-
 LY  PRESCRIBED  TO TREAT, THE MANUFACTURER OF SUCH DRUG, THE NAME OF THE
 GENERIC MANUFACTURER, AND THE LENGTH OF THE DELAY.
   (B) THE ATTORNEY GENERAL  SHALL,  NO  LATER  THAN  THIRTY  DAYS  AFTER
 RECEIVING  A NOTICE PURSUANT TO PARAGRAPH (A) OF THIS SUBDIVISION, SHARE
 THE INFORMATION WITH THE DRUG UTILIZATION REVIEW BOARD ESTABLISHED UNDER
 SECTION THREE HUNDRED SIXTY-NINE-BB OF  THE  SOCIAL  SERVICES  LAW,  ALL
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.

Co-Sponsors

view additional co-sponsors

A7196A (ACTIVE) - Details

See Senate Version of this Bill:
S5169
Law Section:
General Business Law
Laws Affected:
Add §396-rrr, Gen Bus L

A7196A (ACTIVE) - Summary

Enacts the manufacturer disclosure and transparency act requiring prescription drug manufacturers to notify the attorney general of arrangements between pharmaceutical manufacturers resulting in the delay of the introduction of generic medications.

A7196A (ACTIVE) - Bill Text download pdf

 
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
     S. 5169--A                                            A. 7196--A
 
                        2019-2020 Regular Sessions
 
                       S E N A T E - A S S E M B L Y
 
                              April 12, 2019
                                ___________
 
 IN  SENATE  -- Introduced by Sens. BIAGGI, BENJAMIN, CARLUCCI, GAUGHRAN,
   HOYLMAN, JACKSON, MAY,  MYRIE,  PARKER,  SALAZAR  --  read  twice  and
   ordered  printed, and when printed to be committed to the Committee on
   Consumer Protection  --  recommitted  to  the  Committee  on  Consumer
   Protection  in  accordance  with  Senate  Rule  6, sec. 8 -- committee
   discharged, bill amended, ordered reprinted as amended and recommitted
   to said committee
 
 IN ASSEMBLY -- Introduced by  M.  of  A.  DenDEKKER,  MOSLEY,  JACOBSON,
   COLTON,   BUTTENSCHON,   HEVESI,   STIRPE,  REYES,  BARRON,  PICHARDO,
   SEAWRIGHT, CARROLL, LENTOL, LiPETRI,  ASHBY,  WEPRIN,  SIMON,  LIFTON,
   BENEDETTO, D'URSO, HUNTER, MONTESANO, GOTTFRIED, CRUZ -- read once and
   referred to the Committee on Consumer Affairs and Protection -- recom-
   mitted  to the Committee on Consumer Affairs and Protection in accord-
   ance with Assembly Rule  3,  sec.  2  --  committee  discharged,  bill
   amended,  ordered reprinted as amended and recommitted to said commit-
   tee
 
 AN ACT to amend the general  business  law,  in  relation  to  requiring
   prescription  drug  manufacturers  to  notify  the attorney general of
   arrangements between pharmaceutical  manufacturers  resulting  in  the
   delay of the introduction of generic drugs
 
   THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section 1. This act shall be known and may be cited as  the  "manufac-
 turer disclosure and transparency act".
   §  2. The general business law is amended by adding a new section 396-
 rrr to read as follows:
   § 396-RRR. DELAY OF INTRODUCTION OF GENERIC MEDICATIONS. 1.  (A)  EACH
 PHARMACEUTICAL  MANUFACTURER  DOING BUSINESS IN THIS STATE THAT MANUFAC-
 TURES A BRAND NAME PRESCRIPTION DRUG AND  ENTERS  INTO  AN  ARRANGEMENT,
 THROUGH AGREEMENT OR OTHERWISE, WITH ANOTHER PHARMACEUTICAL MANUFACTURER

  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.